Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 6, 2019

Study Completion Date

January 17, 2020

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
BIOLOGICAL

NGM282

OTHER

Placebo

Trial Locations (22)

2050

NGM Clinical Study Site 703, Sydney

3004

NGM Clinical Study Site 701, Melbourne

3065

NGM Clinical Study Site 705, Melbourne

5042

NGM Clinical Study Site 704, Adelaide

22908

NGM Clinical Study Site 904, Charlottesville

23226

NGM Clinical Study Site 911, Richmond

27710

NGM Clinical Study Site 903, Durham

34211

NGM Clinical Study Site 917, Lakewood Rch

38138

NGM Clinical Study Site 921, Germantown

60611

NGM Clinical Study Site 906, Chicago

64131

NGM Clinical Study Site 918, Kansas City

75246

NGM Clinical Study Site 910, Dallas

78229

NGM Clinical Study Site 909, San Antonio

78234

NGM Clinical Study Site 905, San Antonio

78746

NGM Clinical Study Site 920, Rollingwood

85224

NGM Clinical Study Site 922, Chandler

85712

NGM Clinical Study Site 923, Tucson

90057

NGM Clinical Study Site 924, Los Angeles

92103

NGM Clinical Study Site 901, San Diego

98122

NGM Clinical Study Site 908, Seattle

Unknown

NGM Clinical Study Site 902, Denver

00927

NGM Clinical Study Site 916, San Juan

All Listed Sponsors
collaborator

NGM Biopharmaceuticals Australia Pty Ltd

INDUSTRY

lead

NGM Biopharmaceuticals, Inc

INDUSTRY